Clinical Trial Update: Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

Phase III trial completed evaluating a recombinant anti-IL-6 receptor monoclonal antibody added to methotrexate for moderate to severe rheumatoid arthritis; imm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Jamelor (null)
• recombinant anti-interleukin-6 receptor humanized monoclonal antibody injection (anti-IL-6 receptor monoclonal antibody)

Snippet

Sponsor: Zhejiang Hisun Pharmaceutical Co. Ltd. | Conditions: Moderate to Severe Active Rheumatoid Arthritis | Phase 3 | Status: COMPLETED